Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.
Authors:
Open Access
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 25, 100221
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- European Society for Medical Oncology
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
This publication has 39 references indexed in Scilit:
- Clinical features of neuroendocrine prostate cancerEuropean Journal of Cancer, 2019
- DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activationNucleic Acids Research, 2019
- Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for SurvivalCancer Discovery, 2019
- Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer ProgressionPLOS ONE, 2015
- Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel FailureThe Oncologist, 2015
- DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial DrugsChemistry & Biology, 2010
- Gene Panel Model Predictive of Outcome in Men at High-Risk of Systemic Progression and Death From Prostate Cancer After Radical Retropubic ProstatectomyJournal of Clinical Oncology, 2008
- Topoisomerase II-α expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinomaJournal of Clinical Pathology, 2006
- Etoposide in prostate cancerExpert Opinion on Pharmacotherapy, 2000
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996